In Celexir’s sexual and aesthetic wellness toolkit, Kisspeptin is positioned for fertility support, reproductive-axis “reset,” and hormonal rhythm optimization in men and women. Clinicians use it when they want to stimulate the body’s own gonadotropin production rather than layering on exogenous hormones, integrating it alongside sleep, stress, and metabolic care for durable outcomes.
How it works: Kisspeptin sits at the top of the hypothalamic–pituitary–gonadal (HPG) axis. It triggers GnRH release, which in turn elevates LH and FSH, coordinating gonadal steroidogenesis and gametogenesis—effectively tuning the brain–ovary/testis dialogue central to desire, cycle regularity, spermatogenesis, and ovulation. This HPG-axis control is well documented in human and translational studies.
Evidence signals: Beyond physiology, early clinical work shows translational promise. In women undergoing IVF, single-dose kisspeptin-54 successfully triggered oocyte maturation, enabling fertilization and pregnancies in high-risk cohorts. In men with hypoactive sexual desire disorder (HSDD), randomized crossover data show central arousal network modulation with improvements in sexual behavior and penile tumescence—supporting a role in desire-centric dysfunctions while larger studies mature. Together, these findings explain why providers deploy kisspeptin for fertility and hormonal-reset protocols under supervision.
Celexir delivery & specs: Protocols are individualized and often micro-titrated; Celexir supplies GMP, >98% purityinjectable pens with 2–8 °C storage and full documentation (CoA; fertility-use guidance) to keep workflows clean and compliant from warehouse to administration. Position dosing inside a measured plan with objective tracking (cycle metrics, LH/FSH/estradiol or testosterone, semen parameters), and pair with lifestyle pillars for best real-world results.